NCT01225562

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 21,379 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 50 Years – 130 Years
• Healthy volunteers: Not accepted

Summary

This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).

Conditions

• Myocardial Infarction
• Cardiovascular Death
• Atherothrombosis
• Stroke

Interventions

Type	Name	Description
DRUG	Ticagrelor 90 mg	Oral dose twice a day
DRUG	Ticagrelor 60 mg	Oral dose twice a day
DRUG	Ticagrelor Placebo	Oral dose twice a day

Timeline

• Start date: 2010-10-01
• Primary completion: 2014-12-01
• Completion: 2014-12-01
• First posted: 2010-10-21
• Last updated: 2016-01-25
• Results posted: 2015-12-09

Locations

826 sites across 31 countries: United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, France, Germany, Hungary, Italy, Japan, Netherlands, Norway, Peru, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Turkey (Türkiye), Ukraine, United Kingdom